CA
NZ
UK
AU
IND
US
Compass Pathways reported second‑quarter earnings per share of $‑0.36, outperforming the $‑0.41 consensus, but also posted a widened net loss of $253.8 million, or $1.88 per share. The earnings beat came as the company disclosed a cash balance of $433.3 million, positioning it to …
This comparative anchor reflects a modest improvement in underlying financial performance, a important indicator for investors analyzing the company's struggle with profitability. Investor sentiment appears deeply influenced by overall performance concerns, undermining confidence even after this positive outcome.
Dermata Therapeutics, Inc. is set to launch its first commercial product, the Foundational Treatment, priced at $178, starting August 25, 2026. This announcement marks a significant milestone in the company's transition to bringing consumer products to market. The Foundational Treatment package includes four once-weekly …
Akebia Therapeutics, Inc. (NASDAQ: AKBA) reported a second-quarter net loss of $8.9 million on total revenues of $49.1 million, down from $62.5 million a year prior. The company's performance reflects challenges, primarily due to reduced revenues from Auryxia, even as Vafseo sales showed significant …
Arcus Biosciences, Inc. (NYSE: RCUS) achieved an EPS of $-0.72 for the quarter ending June 30, 2026, exceeding analysts' expectations who had predicted a loss of $-0.92. This marks a favorable shift, as the performance demonstrates the company’s commitment to establishing casdatifan as a …
Arcutis Biotherapeutics (NASDAQ: ARQT) reported net product revenue of $129.9 million for the second quarter, a 59% year‑over‑year climb and a 23% sequential jump, while earnings per share reached $0.11 against a $0.04 consensus. The earnings surprise and strong sales lift the company’s cash‑flow …
Bank of America Corp. is investing $250 million annually in GLP-1 weight-loss drugs, a move aimed at enhancing employee health and productivity. This figure underscores the company's commitment to addressing rising healthcare costs associated with obesity-related conditions. The decision reflects a growing trend among …
BeOne Medicines Ltd. reported second quarter revenues of $1.7 billion, a strong increase of 30% compared to the same period last year. This growth was largely propelled by the impressive performance of its leading product, BRUKINSA, which accounted for $1.2 billion in sales, up …
BillionToOne (NASDAQ: BLLN) posted second‑quarter revenue of $109.4 million, a 64% year‑over‑year increase, while earnings per share slipped to $0.15 against a $0.19 consensus estimate. The surge was powered by a $94.2 million boost in prenatal testing and a $13.7 million surge in oncology …
The results come as the board begins a formal review of strategic alternatives, an event likely to shape future valuation.
Please wait processing your request...